The U.S. Food and Drug Administration has signed off on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose. Crucially, suzetrigine creates no euphoria or high like opioids sometimes can, so doctors believe there’s no potential for it to create addiction or dependence in people who use it.
The discovery of a new compound that can kill a drug-resistant bacterium that kills thousands worldwide every year could prove to be a turning point in the fight against antibiotic resistance.
A drug that targets the deadliest form of breast cancer was administered to 16 women in three separate doses in a trial conducted at the Cleveland Clinic with funding from the Pentagon. The trial found that the drug elicits no side effects and triggered an immune response in 75% of patients.
“In our first treated case, we were thrilled to see that the aggressive decline usually seen after birth simply did not appear,” said lead author Professor Darren Orbach of Boston Children’s Hospital.
In an expansion of the company’s “An Accord for a Healthier World” program, which is aimed at increasing access to innovative treatments in some of the world’s poorest countries, Pfizer said it will now offer a total of 500 products.
The University of Auckland team has spent more than a decade developing what they describe as a “bionic” pacemaker, a device designed to respond to the body’s signals in real-time.
Dr. Hiroshi Date—who led the operation—said in a statement that the success of this transplant from living donors can provide optimism among others suffering severe lung damage caused by COVID-19.
A 56-year-old woman from the Bronx, New York, named Sonia Sein is the recipient. She ended up in the hospital six years ago after a particularly nasty asthma attack.
A first-of-its-kind exploratory study, led by researchers from Yale School of Medicine, has found a single dose of the psychedelic psilocybin can reduce migraine frequency by 50 percent for a least two weeks.
In rural Oklahoma, a brand new medical school sits in the Cherokee Nation, training Nation members to become physicians at Nation clinics. Oklahoma State University College of Osteopathic Medicine at the Cherokee Nation is the first tribally associated medical school in the country.
